Prescription of psychotropic medication in patients with type two diabetes mellitus: A multi-practice study from Ireland

Paul Keating\textsuperscript{a}, Ray O’Connor\textsuperscript{a}, Jane O’Doherty\textsuperscript{a}, Ailish Hannigan\textsuperscript{b}, Walter Cullen\textsuperscript{c}, Louise Hickey\textsuperscript{d}, Anne Harnett\textsuperscript{e}, David Meagher\textsuperscript{f} and Andrew O’Regan\textsuperscript{g}

\textsuperscript{a}Department of General Practice, Graduate Entry Medical School, University of Limerick, Limerick, Ireland; \textsuperscript{b}Biostatistics at Graduate Entry Medical School, University of Limerick, Limerick, Ireland; \textsuperscript{c}School of Medicine, Health Sciences, UCD, Dublin, Ireland; \textsuperscript{d}Trinity College Dublin, Dublin, Ireland; \textsuperscript{e}Pharmacology at Graduate Entry Medical School, University of Limerick, Limerick, Ireland; \textsuperscript{f}Psychiatry at Graduate Entry Medical School, University of Limerick, Limerick, Ireland; \textsuperscript{g}General Practice at Graduate Entry Medical School, University of Limerick, Limerick, Ireland

KEY MESSAGES
- Over one in five patients with T2DM in general practice had a current prescription for antidepressants or benzodiazepines
- These patients have higher primary and secondary healthcare utilization
- There is no difference in rates of glycaemic control for patients with or without a current prescription for an antidepressant or a benzodiazepine

ABSTRACT

Background: Comorbid anxiety and depression and type two diabetes mellitus (T2DM) are commonly managed by General Practitioners (GPs).

Objectives: To investigate the proportion of people with T2DM who are prescribed either antidepressant or benzodiazepine medications in general practice; to compare people with T2DM that have a prescription with those that do not in terms of patient characteristics, glycaemic control and healthcare utilization.

Methods: Anonymized data was collected by GPs and senior medical students from electronic medical records of patients with T2DM in 34 Irish general practices affiliated with the University of Limerick Graduate Entry Medical School during the 2013/14 academic year. Data included demographics, healthcare utilization, prescriptions and most recent glycosylated haemoglobin (HbA1c) measurement.

Results: The sample included 2696 patients with T2DM, of which 733 (36.7\%) were female, and with a median age of 66 years. The percentage with a current prescription for an antidepressant or benzodiazepine was 22\% (95\%CI: 18.9–24.9). Those with a current prescription for either drug were more likely to have attended the emergency department (28.3\% vs 15.7\%, $P < 0.001$), to have been admitted to hospital (35.4\% vs 21.3\%, $P < 0.001$) in the past year and attend their GP more frequently (median of 9 vs 7, $P < 0.001$) than those without a prescription. Rates of poor glycaemic control were similar in those with and without a current prescription.

Conclusion: Over one-fifth of people with T2DM in Irish general practice are prescribed an antidepressant or benzodiazepine medication. Prescription of these is associated with increased healthcare utilization but not poorer glycaemic control.

Introduction

Depression and anxiety frequently co-exist in the general population and commonly occur in people with diabetes mellitus with the presence of one increasing the risk of developing the other [1,2]. Furthermore, the comorbid state is associated with poorer outcomes for each condition [3]. Depression occurring in the type two diabetes mellitus (T2DM) population tends to have a particularly strong anxiety component [4]. General practitioners (GPs) are responsible for diagnosing and

ARTICLE HISTORY
Received 26 February 2018
Revised 27 June 2019
Accepted 1 July 2019

KEYWORDS
Antidepressants; benzodiazepines; healthcare utilization; primary care; type two diabetes mellitus
treating most people with T2DM and comorbid depression and anxiety, frequently prescribing benzodiazepine and antidepressant medications [5,6]. As well as their use in the management of depression and anxiety [7], these medications are commonly prescribed to people with untreated and undiagnosed depression [8]. Both classes of medication are associated with significant physical health risks [9,10].

Depression in T2DM has a point prevalence of 10–15% but there is no data on the proportion of people with T2DM that are prescribed an antidepressant or a benzodiazepine medication [11]. When either depression or anxiety, or both, are present in people with diabetes, the risk of mortality increases [12]. The reasons for this are unclear but it is an important clinical point for GPs who manage these conditions daily. Similarly, the effect of comorbid depression and anxiety on glycaemic control remains uncertain [13]. Screening for depression and anxiety is not routinely recommended in the general practice care of people with T2DM, but knowing the patient characteristics that are associated with these conditions may help GPs in their management. Furthermore, research on a range of chronic illness reported that comorbid depression and anxiety symptoms were associated with twice the likelihood of health service use [14]. There is no available data on the effect of these symptoms on the health service use of people with T2DM in general practice. With GPs expected to coordinate secondary care referrals and appropriate use of service resources, knowledge on healthcare utilization among this population is important for health planning [15].

The objectives of this study, therefore, were first, to establish what proportion of people with T2DM were prescribed benzodiazepine or antidepressant medications, and second, to investigate the difference in patients prescribed these medications to those who were not with regard to:

1. Practice and patient characteristics
2. Glycaemic control, using glycosylated haemoglobin (HbA1c)
3. Health service utilization (of primary and secondary healthcare services)

Methods

Study design

This was an observational study involving a retrospective analysis of patient records. It is part of a larger study on the management of patients with T2DM in general practice [16].

Ethics

The Mid-Western Regional Hospital Research Ethics Committee granted ethical approval for the study (22 May 2013).

Study setting

All 51 practices affiliated with the University of Limerick Graduate Entry Medical School, located in the mid-west of Ireland, with a senior medical student on placement in 2013/14 were invited to participate in this study. These practices are based in three of Ireland’s four healthcare regions, which serve a population of 3.5 million. Ireland has a mixed public/private healthcare system, with approximately 43% of the population eligible for free healthcare [17]. At the time of data collection, there was no structured delivery of care nationally to patients with T2DM in primary care in Ireland.

Study sample

Senior medical students on placement and their GP supervisors used existing diabetes registers or reporting functions of electronic practice management systems to generate a list of all patients with T2DM in the practice. Where no register existed, patients were identified using disease coding, medications or the recording of the use of blood glucose monitors in the practice management system. The practice team reviewed all lists to ensure they were up to date and complete. For feasibility of detailed data extraction and to ensure comparable workload for students on placement across practices, in practices with over 100 patients with T2DM, a random sample of 100 patients was selected using the random number function in Microsoft Excel.

Measurements

A standardized data extraction tool was used to record the following information for those patients with T2DM who had consulted with their GP in the previous year (1 September 2012 to 31 August 2013):

- Age
- Gender
- Eligibility for free healthcare
- Current prescription for antidepressants or benzodiazepine
- Smoking status: current smoker, non-smoker or smoking status not recorded in the previous year
- Body mass index (BMI): BMI < 25 kg/m²; BMI of 25–30 kg/m²; BMI ≥ 30 kg/m² or BMI not recorded in the previous year
- Healthcare utilization in the previous year: total number of GP consultations where a consultation is defined as any visit or telephone conversation that resulted in an entry to patient records; any attendance to the emergency department; any hospital admission; any referral or attendance to specialist mental health services; any referral or attendance to an endocrinologist
- most recent measurement of HbA1c in mmol/mol. Poor glycaemic control was defined as HBA1c greater than 8% (64 mmol/mol)
- whether the practice was in an urban (concentrated geographical area with 5000 or more residents), rural (scattered population over a large geographical area) or mixed urban/rural location (both concentrated and scattered population) [18]
- a classification of the deprivation of the area in which the practice was located based on the All-Ireland HP Deprivation Index [19]
- the number of full-time GPs in the practice
- the number of part-time and full-time practice nurses
- whether the practice was a member of a primary care team

Data were entered using the standardized data template in each practice and anonymized data sets from all practices were merged into a master file.

Statistical analyses

The proportion of patients with a current prescription for antidepressants or benzodiazepines was estimated with a 95%CI for the proportion, using the SAS procedure SURVEYFREQ to account for clustering of patients within practices. Demographic and healthcare utilization variables were summarized using graphical and numeric descriptive statistics. Medians were compared across groups (those with a current prescription, those without) using non-parametric tests and Pearson’s chi-squared test was used to investigate associations between categorical variables. A multiple logistic regression analysis was carried out to measure associations between current antidepressant or benzodiazepine prescription (yes/no) using both patient level characteristics and practice level characteristics as explanatory variables. A 5% level of significance was used for all tests and odds ratios with 95%CIs are reported.

Results

Practices

Out of the 51 practices were invited to participate in this study and a total of 34 practices participated (67% of eligible practices). Practice size ranged from 1169–22 352 patients with a median of 5160 patients. Most (79%) of participating practices had an existing diabetes register. All patients with T2DM were included from half of the participating practices with the numbers of less than 100, and, in the remaining half of practices, a random sample of 100 patients with T2DM was selected. Table 1 outlines the characteristics of participating practices (n = 34 practices).

Patients with and without a prescription for a psychotropic drug

The final sample was 2696 patients with T2DM who had visited their GP in the previous year. The median age of the sample was 67 years (range: 11–100 years) and the majority of the sample were male (61%) and eligible for free healthcare (77%). The percentage of patients with T2DM with a current prescription for an antidepressant or benzodiazepine was 22% (95%CI: 18.9–24.9).

Table 2 compares the characteristics and healthcare utilization of patients with and without a current prescription. Those with a current prescription for antidepressants or benzodiazepines were more likely to be female, eligible for free healthcare and be recorded as a current smoker compared to those without a current prescription (Table 2). Those with a current prescription were more likely to have attended the emergency department, be admitted to hospital, have been referred to or attended specialist mental health

Table 1. Characteristics of participating practices (n = 34 practices).

| Practice characteristics | Practices n (%) |
|--------------------------|-----------------|
| Number of full-time GPs  |                 |
| One/two                  | 17 (50)         |
| Three/four               | 17 (50)         |
| Practice nurse           |                 |
| Full-time                | 20 (58.8)       |
| Part-time                | 14 (41.2)       |
| Location                 |                 |
| Urban                    | 8 (23.5)        |
| Rural                    | 14 (41.2)       |
| Mixed urban/rural        | 12 (35.3)       |
| Member of a primary care team | 11 (32.4) |
| Deprivation index        |                 |
| Disadvantaged            | 10 (29.4)       |
| Marginally below average | 13 (38.2)       |
| Marginally above average | 8 (23.5)        |
| Affluent                 | 3 (8.8)         |
services in the past year and consult with their GP more frequently compared to those without a current prescription (Table 2). There were no differences in age, BMI or the rates of referral/attendance to an endocrinologist between the two groups.

**The relationship between glycaemic control and psychotropic drug use**

A recent measurement (within the previous 12 months) of HbA1c was available for 88% of the patients (n = 2362). The distributions of the most recent measurement of HbA1c were similar for both groups (Table 2).

Using a cut-off of greater than 8% (64 mmol/mol) to represent poor glycaemic control, a similar proportion (of approximately 18.3%) in both groups were above the cut-off point.

**Factors associated with prescription of psychotropic drugs**

A multiple logistic regression analysis to measure associations between practice and patient characteristics with having a current prescription for antidepressants or benzodiazepines identified that female gender, being eligible for free healthcare, being a current smoker and consulting with the GP more frequently were independently associated with statistically significant increased odds of having a current prescription (Table 3). An urban location for the practice was also associated with statistically significant increased odds of having a current prescription (Table 3).

**Discussion**

**Main findings**

This study, conducted in 34 practices in Ireland, including 2696 patients with T2DM who had visited

| Table 2. Characteristics and healthcare utilization of patients with type two diabetes mellitus, with or without a current prescription for antidepressants or benzodiazepine. |
|---|
| Patients without a current prescription (n = 2106) | Patients with a current prescription (n = 590) | P-value |
| **Age** | 66 years (11–100 years) | 67 years (27–96 years) | 0.22 |
| **Female gender** | 733 (36.7%) | 287 (48.6%) | <0.001 |
| **Eligible for free healthcare** | 1566 (74.5%) | 519 (88.1%) | <0.001 |
| **Current smoking status** | 1015 (48.2%) | 286 (48.5%) | <0.001 |
| **BMI not recorded** | 1056 (50.2%) | 305 (51.7%) | 0.13 |
| **BMI <25 kg/m²** | 129 (6.1%) | 31 (5.3%) |
| **BMI 25–30 kg/m²** | 386 (18.3%) | 87 (14.7%) |
| **BMI ≥30 kg/m²** | 535 (25.4%) | 167 (28.3%) |
| **HbA1c** | 6.8% (51 mmol/mol) | 6.8% (51 mmol/mol) |
| **Number of GP consultations** | 6.3–7.6% | 6.3–7.7% |
| **Exceeds cut-off point of 8% (64 mmol/mol)** | 18.2% | 18.9% | 0.71 |
| **Number of GP consultations** | 7 | 9 | <0.001 |
| **First to third quartile** | 3–12 | 5–16 |
| **Secondary healthcare utilization** | 331 (15.7%) | 167 (28.3%) | <0.001 |
| **Attendance at the emergency department** | 447 (21.2%) | 110 (18.6%) | 0.17 |
| **Referral/attendance to endocrinologist** | 24 (1.1%) | 128 (21.7%) | <0.001 |
| **Hospital admission** | 448 (21.3%) | 209 (35.4%) | <0.001 |

| Table 3. Multiple logistic regression of current antidepressant or benzodiazepine prescription (yes, no) in patients with type two diabetes mellitus (n = 2,696) |
|---|
| **Explanatory variable** | Odds ratio (95%CI) | P-value |
| **Patient characteristics** |  |  |
| Gender |  |  |
| Female gender (male = 1) | 1.43 (1.16–1.78) | 0.0009 |
| Eligible for free healthcare (no = 1) | 2.17 (1.62–2.90) | <0.0001 |
| Number of GP consultations | 1.04 (1.02–1.05) | <0.0001 |
| Smoking status (non-smoker = 1) | 1.74 (1.26–2.40) | 0.0014 |
| Unknown | 1.24 (0.92–1.67) | 0.64 |
| **Practice characteristics** |  |  |
| Practice location (mixed = 1) | 1.55 (1.11–2.16) | 0.0005 |
| Rural | 0.86 (0.56–1.32) | 0.052 |

*Final model presented with all variables statistically significant (P < 0.05).*
their GP in the previous year, found 22% of these patients had a prescription for an antidepressant or benzodiazepine. Those with a current prescription were more likely to have attended the emergency department, be admitted to hospital, have attended specialist mental health services in the past year or have attended the GP more frequently compared to those without a prescription. There was no significant difference between rates of glycaemic control for those with or without a current prescription for antidepressants or benzodiazepines. In a multivariable model, we identified five independent factors associated with the prescription of a psychotropic drug in this population: female gender, frequent attendance to the GP, tobacco smoking, attendance at urban centres and eligibility for free healthcare.

Prevalence of psychotropic drug prescription

The figure of 22% of the T2DM population in this study prescribed these drugs may be explained by previous findings that up to 20% of people with any type of diabetes mellitus have a major depressive disorder [20].

A recent study of benzodiazepine prescribing showed that the rate of prescribing has been decreasing in Ireland [21]. The paper reported that in 2015 the rate of prescribing of benzodiazepines in the general population was 16.6% [21]. Similarly, antidepressant prescribing rates vary between countries, from 3% in Dutch centres to 9% in UK centres [22]. The most recent available analysis in Ireland reports an antidepressant prescribing rate of 5% [23]. In broad terms, the combined prescribing rates in the general population do not appear to be dissimilar to the prescribing rate of people with T2DM reported in this study. However, a crude combination would likely overestimate the actual numbers prescribed these medications as it would twice include the significant number of people likely be prescribed both drugs.

Psychotropic drugs and glycaemic control

Our finding that glycaemic control, as measured by HBA1c, is not significantly associated with antidepressant or benzodiazepine use, contributes new information to an important clinical question. The relationship between mood and glycaemic control is unclear, with one study finding that depressive symptoms were not associated with poor glycaemic control in T2DM [24], while another study showed a sustained improvement in mood was associated with improved glycaemic control in T2DM [25]. In this study, a less stringent cut-off point was applied because of the presence of older age profile and presence of comorbidities [26]. This may lead to a comparatively lower proportion of people with ‘poor’ glycaemic control.

Psychotropic drugs and healthcare utilization

While people that are prescribed antidepressants or benzodiazepines had similar glycaemic control to those that did not, they were more likely to attend the GP as well as secondary care services. The fact that an underlying psychological condition is expected to be present may explain the higher attendance to specialist mental health services, but the study also found higher attendances at the emergency department as well as being more likely to be admitted to hospital. Interestingly, the rates of attendance at specialist endocrinology services were similar, suggesting that there may not necessarily be a higher rate of diabetes-related complications among people prescribed these medications. The presence of comorbid major depression in any physical condition is linked to approximately double the likelihood of healthcare utilization [14]. High-risk health behaviour, including smoking, and increased incidence of adverse heart events have been reported in people with depression in T2DM [27] and this may account for the increased use of emergency departments and inpatient admissions. The increased secondary care utilization has health service planning implications as management of T2DM in primary care is much more cost-effective [28] and people with the condition who are managed in primary care have better indices of quality of life with similar health outcomes compared to secondary care [29].

Factors associated with prescription of psychotropic drugs

The association we found with female gender could be explained by research showing that women with a physical illness were more likely to access mental health services than men and that for women more than men with depressive symptoms [30], the risk of developing T2DM is higher [31]. The association with higher GP attendance rates is similar to findings reported by Brieler et al., and is possibly because the high prevalence of anxiety-related symptoms may increase these patients’ attendance rates [25,32]. We found no higher prescribing prevalence in people with
T2DM in areas of social deprivation but prevalence was higher in people who were eligible for unrestricted public medical care (mostly lower income) similar to Jacob et al. [33]. The association with smoking and having a prescription for a psychotropic medication is consistent with previous research showing increased rates of smoking in people that are prescribed this medication [34].

Strengths and limitations
The strengths of this study include the large sample size of clinical records of patients reviewed across a large number of practices and the scope of the examination of clinical records. The practices that participated are considered a representative sample of all practices by size, urban/rural location and patient eligibility for free care.

Study limitations include that we only can say that benzodiazepine or antidepressant drugs were or were not prescribed. We have used prescribing as a proxy for mental illness while acknowledging that a minority of prescriptions for these medications may be used for the treatment of neuropathic pain or sleep disorders. The observational design of this study limits the strength of the conclusions we can draw about the differences between those with a current prescription or not. We also have not compared our results on patients with T2DM to patients without T2DM who are currently prescribed antidepressants or benzodiazepines. No exact dates of measurement for HbA1c were collected but all measurements were taken within the previous 12 months. Lastly, objective glucose measurements, with which to make comparisons, were not available.

Further research
The authors recommend that future research should focus on the reasons for increased secondary healthcare use in patients with a current prescription and the appropriateness of this use, particularly of the emergency department.

Conclusion
This study highlights that, among a T2DM general practice population, over one in five are prescribed antidepressant and benzodiazepine medication. Having a prescription for these medications is associated with increased secondary healthcare use, in particular attendance at emergency departments and hospital admission, which has serious implications for individual health, quality of life and health service planning.

Acknowledgements
The authors thank the medical students and GPs who were involved in collecting this data. AH, LH and AOR have contributed to the study design, LH and AH designed the coding search, all authors developed the data analysis. All authors have contributed to the development of the manuscript, general discussion and manuscript review.

Disclosure statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References
[1] Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005;62:617–627.
[2] Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009;26:153–161.
[3] Wayne J, Katon MD. The comorbidity of diabetes mellitus and depression. Am J Med. 2008;121:S8–S15.
[4] Starkstein SE, Davis WA, Dragovic M, et al. Diagnostic criteria for depression in type 2 diabetes: a data-driven approach. PLoS One. 2014;9:e112049.
[5] Hermanns N, Caputo S, Dzida G, et al. Screening, evaluation and management of depression in people with diabetes in primary care. Prim Care Diabetes. 2013;7:1–10.
[6] Carrier JD, Roberge P, Courteau J, et al. Predicting chronic benzodiazepine use in adults with depressive disorder: retrospective cohort study using administrative data in Quebec. Can Fam Physician. 2016;62:e473–483.
[7] Leggett A, Kavanagh J, Zivin K, et al. The association between benzodiazepine use and depression outcomes in older veterans. J Geriatr Psychiatry Neurol. 2015;28:281–287.
[8] Lee D, Martini N, Moyes S, et al. Potentially inappropriate medication use: the Beers’ Criteria used among older adults with depressive symptoms. J Prim Health Care. 2013;5:182–190.
[9] Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. Br Med J. 2014;348:g1996.
[10] Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–598.

[11] Blay SL, Fillenbaum GG, Marinho V, et al. Increased health burden associated with comorbid depression in older Brazilians with diabetes. J Affect Disord. 2011;134:77–84.

[12] Naicker K, Johnson JA, Skogen JC, et al. Type 2 diabetes and comorbid symptoms of depression and anxiety: longitudinal associations with mortality risk. Dia Care. 2017;40:352–358.

[13] Semenkovich K, Brown ME, Svrakic DM, et al. Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. Psychol Med. 2006;36:587–596.

[14] Stein MB, Cox BJ, Afifi TO, et al. Does co-morbid depressive illness affect the impact of chronic physical illness? A population-based perspective. Psychol Med. 2006;36:587–596.

[15] Greenfield G, Foley K, Majeed A. Rethinking primary care’s gatekeeper role. BMJ. 2016;354:i4803.

[16] Gettings J, O’Connor R, O’Doherty J, et al. A snapshot of type two diabetes mellitus management in general practice prior to the introduction of diabetes Cycle of Care. Ir J Med Sci. 2018;187:953–957.

[17] Department of Health: Health in Ireland Key Trends 2016 [Internet]. Ireland: Department of Health; c2016 [cited 2019 Jun 16]. Available from: https://health.gov.ie/wp-content/uploads/2016/12/Health_in_Ireland_KeyTrends2016.pdf.

[18] O’Kelly M, Teljeur C, O’Kelly F, et al. Structure of general practice in Ireland 1982–2015. Dublin: Trinity College Dublin; 2016.

[19] Trutz Hasse: All Island HP Deprivation Index [Internet]. Dublin: Health Research Board; c2012. [cited 2019 Jun 16] Available from: http://trutzhaase.eu/wp/wp-content/uploads/AIRO-2011-All-Island-HP-Deprivation-Index.jpg.

[20] Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care. 1993;16:1167–1178.

[21] Cadogan CA, Ryan C, Cahir C, et al. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol. 2018;84:1354–1363.

[22] Abbting-Karahagopian VC, Huerta PC, Souverein F, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol. 2014;70:849–857.

[23] Drugnet I, Use of sedatives or tranquillisers and anti-depressants [Internet]. Ireland: Health Research Board; c2012. [cited 2019 Jun 16] Available from: https://www.hrb.ie/fileadmin/publications_files/Drugnet_44_-_Web.pdf

[24] Aikens JE, Perkins DW, Lipton B, et al. Longitudinal analysis of depressive symptoms and glycemic control in type 2 diabetes. Diabetes Care. 2009;32:1177–1181.

[25] Brieler JA, Lustman PJ, Scherrer JF, et al. Antidepressant medication use and glycemic control in co-morbid type 2 diabetes and depression. Fam Pract. 2016;33:30–36.

[26] American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35:11–63.

[27] Higgins TS, Jr, Ritchie CS, Stetson BA, et al. An examination of the moderating effect of treatment with anti-depressants on the association of heart disease with depression in males with type 2 diabetes attending a Veterans Affairs Medical Center. Diabetes Res Clin Pract. 2007;2:220–228.

[28] Nolan JJ, O’Halloran D, McKenna TJ, et al. The cost of treating type 2 diabetes (CODEIRE). Ir Med J. 2006;99:307–310.

[29] Collins MM, O’Sullivan T, Harkins V, et al. Quality of life and quality of care in patients with diabetes experiencing different models of care. Diabetes Care. 2009;32:603–605.

[30] Matheson FI, Smith KLW, Fazli GS, et al. Physical health and gender as risk factors for usage of services for mental illness. J Epidemiol Community Health. 2014;68:971–978.

[31] Demmer RT, Gelb S, Suglia SF, et al. Sex differences in the association between depression, anxiety, and type 2 diabetes mellitus. Psychosom Med. 2015;77:467–477.

[32] Engum A. The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res. 2007;62:31–38.

[33] Jacob L, Kostev K. Prevalence of depression in type 2 diabetes patients in German primary care practices. J Diabetes Complicat. 2016;30:432–437.

[34] Kopp M, Fleischhacker WW, Stürz K, et al. Poor health behaviour and reduced quality of life of people treated with psychotropic drugs. Hum Psychopharmacol Clin Exp. 2011;26:161–167.